{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:53:08Z","timestamp":1773373988328,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T00:00:00Z","timestamp":1253318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T00:00:00Z","timestamp":1253318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10637-009-9318-5","type":"journal-article","created":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T05:25:57Z","timestamp":1253251557000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"William R.","family":"Schelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Phung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,19]]},"reference":[{"key":"9318_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"9318_CR2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2001.19.9.2509","volume":"19","author":"DM Savarese","year":"2001","unstructured":"Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509\u20132516","journal-title":"J Clin Oncol"},{"key":"9318_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"9318_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520","journal-title":"N Engl J Med"},{"key":"9318_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/annonc\/mdn288","volume":"19","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749\u20131753","journal-title":"Ann Oncol"},{"key":"9318_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc990","volume":"3","author":"J Nelson","year":"2003","unstructured":"Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110\u2013116","journal-title":"Nat Rev Cancer"},{"key":"9318_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1056\/NEJM199509073331023","volume":"333","author":"ER Levin","year":"1995","unstructured":"Levin ER (1995) Endothelins. N Engl J Med 333:356\u2013363","journal-title":"N Engl J Med"},{"key":"9318_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1440-1681.1999.03014.x","volume":"26","author":"RG Goldie","year":"1999","unstructured":"Goldie RG (1999) Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 26:145\u2013148","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"9318_CR9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0031-6997(25)06809-7","volume":"46","author":"GM Rubanyi","year":"1994","unstructured":"Rubanyi GM, Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325\u2013415","journal-title":"Pharmacol Rev"},{"key":"9318_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1043-2760(98)00094-0","volume":"9","author":"A Bagnato","year":"1998","unstructured":"Bagnato A, Catt KJ (1998) Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 9:378\u2013383","journal-title":"Trends Endocrinol Metab"},{"key":"9318_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.74.1.223","volume":"74","author":"ML Casey","year":"1992","unstructured":"Casey ML, Byrd W, MacDonald PC (1992) Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 74:223\u2013225","journal-title":"J Clin Endocrinol Metab"},{"key":"9318_CR12","first-page":"663","volume":"56","author":"JB Nelson","year":"1996","unstructured":"Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663\u2013668","journal-title":"Cancer Res"},{"key":"9318_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0022-5347(17)35083-8","volume":"151","author":"S Kobayashi","year":"1994","unstructured":"Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H (1994) Localization of endothelin receptors in the human prostate. J Urol 151:763\u2013766","journal-title":"J Urol"},{"key":"9318_CR14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0026-895X(25)09928-6","volume":"45","author":"S Kobayashi","year":"1994","unstructured":"Kobayashi S, Tang R, Wang B, Opgenorth T, Langenstroer P, Shapiro E, Lepor H (1994) Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol 45:306\u2013311","journal-title":"Mol Pharmacol"},{"key":"9318_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm0995-944","volume":"1","author":"JB Nelson","year":"1995","unstructured":"Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944\u2013949","journal-title":"Nat Med"},{"key":"9318_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm0198-050","volume":"4","author":"CN Papandreou","year":"1998","unstructured":"Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50\u201357","journal-title":"Nat Med"},{"key":"9318_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0090-4295(98)00658-X","volume":"53","author":"JB Nelson","year":"1999","unstructured":"Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53:1063\u20131069","journal-title":"Urology"},{"key":"9318_CR18","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1210\/en.130.6.3617","volume":"130","author":"AS Alam","year":"1992","unstructured":"Alam AS, Gallagher A, Shankar V, Ghatei MA, Datta HK, Huang CL, Moonga BS, Chambers TJ, Bloom SR, Zaidi M (1992) Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 130:3617\u20133624","journal-title":"Endocrinology"},{"key":"9318_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","volume":"21","author":"MA Carducci","year":"2003","unstructured":"Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679\u2013689","journal-title":"J Clin Oncol"},{"key":"9318_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1054\/bjoc.2000.1261","volume":"83","author":"JW Chiao","year":"2000","unstructured":"Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, Ahmed T (2000) Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83:360\u2013365","journal-title":"Br J Cancer"},{"key":"9318_CR21","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/cncr.22996","volume":"110","author":"MA Carducci","year":"2007","unstructured":"Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959\u20131966","journal-title":"Cancer"},{"key":"9318_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","volume":"20","author":"JW Growcott","year":"2009","unstructured":"Growcott JW (2009) Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 20:83\u201388","journal-title":"Anticancer Drugs"},{"key":"9318_CR23","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/sj.bjc.6602676","volume":"92","author":"CD Morris","year":"2005","unstructured":"Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ (2005) Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92:2148\u20132152","journal-title":"Br J Cancer"},{"key":"9318_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","volume":"55","author":"ND James","year":"2009","unstructured":"James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA (2009) Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial. Eur Urol 55:1112\u20131123","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"9318_CR25","first-page":"S95","volume":"82","author":"B Zonnenberg","year":"2008","unstructured":"Zonnenberg B, Borre M, Beuzeboc P, Payne H, Culine S, Morris T, Phung D, James N (2008) The effect of ZD4054 on bone metastasis in patients with M1 hormone-resistant prostate cancer. Calcif Tissue Int 82(Suppl 1):S95 abst P093","journal-title":"Calcif Tissue Int"},{"key":"9318_CR26","first-page":"1059","volume":"1","author":"A Bagnato","year":"1995","unstructured":"Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ (1995) Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1:1059\u20131066","journal-title":"Clin Cancer Res"},{"key":"9318_CR27","first-page":"6381","volume":"62","author":"A Bagnato","year":"2002","unstructured":"Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A (2002) Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 62:6381\u20136384","journal-title":"Cancer Res"},{"key":"9318_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0014-2999(00)00198-9","volume":"396","author":"J Drimal","year":"2000","unstructured":"Drimal J, Drimal J Jr, Drimal D (2000) Enhanced endothelin ET(B) receptor down-regulation in human tumor cells. Eur J Pharmacol 396:19\u201322","journal-title":"Eur J Pharmacol"},{"key":"9318_CR29","first-page":"1273","volume":"1","author":"MJ Grimshaw","year":"2002","unstructured":"Grimshaw MJ, Naylor S, Balkwill FR (2002) Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 1:1273\u20131281","journal-title":"Mol Cancer Ther"},{"key":"9318_CR30","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.1073\/pnas.96.20.11496","volume":"96","author":"R Lahav","year":"1999","unstructured":"Lahav R, Heffner G, Patterson PH (1999) An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 96:11496\u201311500","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9318_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2006.02.007","volume":"246","author":"BR Pflug","year":"2007","unstructured":"Pflug BR, Zheng H, Udan MS, D\u2019Antonio JM, Marshall FF, Brooks JD, Nelson JB (2007) Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 246:139\u2013148","journal-title":"Cancer Lett"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9318-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9318-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:18:13Z","timestamp":1739344693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9318-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["9318"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9318-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,19]]},"assertion":[{"value":"29 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}